Patents by Inventor Jeffrey Robl

Jeffrey Robl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel inhibitors of kinases
    Publication number: 20050124621
    Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Application
    Filed: January 13, 2005
    Publication date: June 9, 2005
    Inventors: Rajeev Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
  • HMG-CoA reductase inhibitors and method
    Publication number: 20050085497
    Abstract: Compounds are provided having the following structure which are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholsterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis wherein X is N or CR5; and pharmaceutically acceptable salts thereof, wherein R1 to R7 are as defined herein. A method for treating the above diseases employing the above compounds is also provided.
    Type: Application
    Filed: September 21, 2004
    Publication date: April 21, 2005
    Inventors: Saleem Ahmad, Jeffrey Robl, Khehyong Ngu
  • Imidazolyl inhibitors of 15-lipoxygenase
    Publication number: 20050070588
    Abstract: The present invention provides imidazolyl inhibitors of 15-LO, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.
    Type: Application
    Filed: September 1, 2004
    Publication date: March 31, 2005
    Inventors: David Weinstein, Khehyong Ngu, Jeffrey Robl
  • Pyrazolyl inhibitors of 15- lipoxygenase
    Publication number: 20050070589
    Abstract: The present invention provides pyrazolyl inhibitors of 15-LO, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.
    Type: Application
    Filed: September 1, 2004
    Publication date: March 31, 2005
    Inventors: Khehyong Ngu, David Weinstein, Jeffrey Robl
  • Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
    Publication number: 20050038020
    Abstract: Compounds are provided having the formula (I) wherein: n is 0, 1 or 2; m is 0, 1 or 2; the sum of n+m less then or equal to 2; the dashed bonds forming a cyclopropyl ring can only be present when Y is CH; X is H or CN; Y is CH, CH2, CHF, CF2, O, S, SO, or SO2; and A is adamantyl. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: July 27, 2004
    Publication date: February 17, 2005
    Inventors: Lawrence Hamann, Ashish Khanna, Mark Kirby, David Magnin, Ligaya Simpkins, James Sutton, Jeffrey Robl
  • Method for treating atherosclerosis employing an aP2 inhibitor and combination
    Publication number: 20040229807
    Abstract: A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.
    Type: Application
    Filed: June 21, 2004
    Publication date: November 18, 2004
    Inventors: Jeffrey A. Robl, Rex A. Parker, Scott A. Biller, Haris Jamil, Bruce L. Jacobson, Krishna Kodukula
  • HMG-CoA reductase inhibitors and method
    Patent number: 6812345
    Abstract: Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis and pharmaceutically acceptable salts thereof, wherein X is O, S, SO, SO2 or NR7; Z is n is 0 or 1; R1 and R2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; and R3 to R10 are as defined herein.
    Type: Grant
    Filed: June 24, 2003
    Date of Patent: November 2, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, Bang-Chi Chen, Chong-Qing Sun
  • Bicyclic modulators of androgen receptor function
    Publication number: 20040181064
    Abstract: The invention provides compounds according to formula I 1
    Type: Application
    Filed: February 17, 2004
    Publication date: September 16, 2004
    Inventors: Chong-Qing Sun, Lawrence Hamann, David Augeri, Yingzhi Bi, Jeffrey Robl, Yan-Ting Huang, Tammy Wang, Alexandra Holubec, Ligaya Simpkins, James C. Sutton, James J. Li
  • N-formyl hydroxylamine containing compounds useful as ACE inhibitors and/or NEP inhibitors
    Patent number: 6777550
    Abstract: N-formyl hydroxylamines are provided which have the structure wherein R is H, alkyl, alkenyl, aryl-(CH2)p—, heteroaryl-(CH2)p— or cycloheteroalkyl-(CH2)p— R1 is H or COR2 where R2 is alkyl, aryl-(CH2)p—, cycloheteroalkyl-(CH2)p—, heteroaryl-(CH2)p—, alkoxy or cycloalkyl-(CH2)p—, p is 0 to 8, and A is a dipeptide derived from an amino acid or is a conformationally restricted dipeptide mimic. The above compounds are useful in treating hypertension congestive heart failure, renal failure, and hepatic cirrhosis.
    Type: Grant
    Filed: April 4, 1997
    Date of Patent: August 17, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventor: Jeffrey A. Robl
  • HMG-CoA reductase inhibitors and method
    Publication number: 20040092573
    Abstract: Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis 1
    Type: Application
    Filed: June 24, 2003
    Publication date: May 13, 2004
    Inventors: Jeffrey A. Robl, Bang-Chi Chen, Chong-Qing Sun
  • Heterocyclic aromatic compounds useful as growth hormone secreagogues
    Publication number: 20040072881
    Abstract: Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.
    Type: Application
    Filed: October 28, 2002
    Publication date: April 15, 2004
    Inventors: Jeffrey A. Robl, Joseph A. Tino, Andres S. Hernandez, Jun Li
  • Heterocyclic aromatic compounds useful as growth hormone secretagogues
    Publication number: 20040029935
    Abstract: Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.
    Type: Application
    Filed: October 28, 2002
    Publication date: February 12, 2004
    Inventors: Jeffrey A. Robl, Joseph A. Tino, Andres S. Hernandez, Jun Li
  • HMG-CoA reductase inhibitors and method
    Publication number: 20040024216
    Abstract: Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis 1
    Type: Application
    Filed: June 24, 2003
    Publication date: February 5, 2004
    Inventors: Jeffrey A. Robl, Bang-Chi Chen, Chong-Qing Sun
  • Bicyclic modulators of androgen receptor function
    Publication number: 20040019063
    Abstract: The invention provides for a pharmaceutical composition capable of modulating the androgen receptor comprising a compound of formula I 1
    Type: Application
    Filed: May 15, 2003
    Publication date: January 29, 2004
    Inventors: Chongqing Sun, Lawrence Hamann, David Augeri, Yingzhi Bi, Jeffrey Robl, Yanting Huang, Tammy Wang, Alexandra Holubec, Ligaya Simpkins
  • Heterocyclic aromatic compounds useful as growth hormone secretagogues
    Publication number: 20040002525
    Abstract: Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.
    Type: Application
    Filed: October 28, 2002
    Publication date: January 1, 2004
    Inventors: Jeffrey A. Robl, Joseph A. Tino, Andres S. Hernandez, Jun Li
  • Pyridone inhibitors of fatty acid binding protein and method
    Patent number: 6670380
    Abstract: Compounds are provided having the formula: wherein A, Q, and X are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such compounds alone or in combination with other antidiabetic agents such as metformin, glyburide, troglitazone and/or insulin.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: December 30, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Richard Sulsky, Jeffrey A. Robl
  • Bicyclic modulators of androgen receptor function
    Patent number: 6670386
    Abstract: The invention provides compounds of the formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: December 30, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chongqing Sun, Jeffrey A. Robl, Mark E. Salvati, Tammy Wang, Lawrence Hamann, David Augeri
  • Heterocyclic aromatic compounds useful as growth hormone secretagogues
    Patent number: 6660760
    Abstract: Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength. The heterocyclic aromatic compounds have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, wherein Xa is heteroaryl, preferably,  and R1, R1a, R6, Y, Xb, A, B, Z, R3, R4, R4a, R5 and R5a are as defined herein.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: December 9, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Jeffrey A. Robl, Joseph A. Tino, Andres S. Hernandez, Jun Li
  • Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
    Publication number: 20030225091
    Abstract: Compounds that are dual aP2/k-FABP inhibitors are provided having the formula 1
    Type: Application
    Filed: November 15, 2002
    Publication date: December 4, 2003
    Inventors: David R. Magnin, Richard B. Sulsky, Jeffrey A. Robl, Thomas J. Caulfield, Rex A. Parker
  • Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
    Patent number: 6649622
    Abstract: aP2 inhibiting compounds are provided having the formula wherein A, B, X, and Y are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: November 18, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard Sulsky, Jeffrey A. Robl